Rates of surgical site infections and length of stay following major gynecologic oncology surgery for patients on federally funded insurance: A 6-month retrospective cohort.

Phase 1 trial of GD2-SADA: 177 Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and ...

Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.

Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.

Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer.

Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF V600-positive melanoma: Interim analysis of the ...

Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAF V600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.

Effectiveness and safety outcomes in patients with EBV + PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe.

Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG).

Toxicity reporting consistency and subjective minimizing language use in colorectal cancer (CRC) and pancreatic cancer (PaC) clinical trials: A systematic review of phase III randomized controlled ...

Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177 Lu-PSMA-617.

Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAF V600 mutation-positive advanced melanoma: Second interim OS ...